Related Experiment Video

Updated: Dec 24, 2025

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer
09:40

Author Spotlight: Unveiling the Role of TMOD3 in Platinum Resistance and Immune Infiltration in Ovarian Cancer

Published on: August 2, 2024

3.1K

SET and MYND domain-containing protein 3 inhibits tumor cell sensitivity to cisplatin

Lei Wang1,2, Man-Li Xu1,2, Chang Wang1,2

  • 1Key Laboratory of Industrial Fermentation Microbiology, Tianjin University of Science and Technology, Ministry of Education, Tianjin 300457, P.R. China.

Oncology Letters
|April 10, 2020
PubMed

Insights

SET and MYND domain-containing protein 3 (SMYD3) impacts tumor sensitivity to cisplatin chemotherapy. Reducing SMYD3 enhances cisplatin effectiveness, suggesting SMYD3 as a target for overcoming cisplatin resistance in cancer treatment.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Cisplatin resistance is a significant challenge in cancer chemotherapy.
  • SET and MYND domain-containing protein 3 (SMYD3), a histone methyltransferase, is implicated in tumor development.

Purpose of the Study:

  • To investigate the role of SMYD3 in cisplatin resistance in breast cancer cells.
  • To determine if SMYD3 affects tumor cell sensitivity to cisplatin chemotherapy.

Main Methods:

  • Real-time quantitative PCR (qPCR) and Western blotting to assess SMYD3 expression.
  • Luciferase reporter assays to evaluate transcriptional activity.
  • MTT and clonogenic assays to measure cell viability and proliferation.
  • Small interfering RNA (siRNA) for SMYD3 knockdown and plasmid transfection for overexpression.

Main Results:

  • SMYD3 showed differential expression in MCF-7 and T47D breast cancer cells, correlating with cisplatin resistance.
  • SMYD3 knockdown increased cisplatin sensitivity and enhanced cisplatin-induced apoptosis.
  • SMYD3 overexpression decreased cisplatin sensitivity.
  • SMYD3 expression and its 3'-untranslated region's transcriptional activity were downregulated during cisplatin treatment.

Conclusions:

  • SMYD3 plays a role in regulating sensitivity to cisplatin chemotherapy.
  • SMYD3 contributes to the development of cisplatin resistance.
  • MicroRNA-124 may be involved in SMYD3-mediated regulation of cisplatin resistance.
Keywords:
SET and MYND domain containing 3cisplatin sensitivitytumor cells

More Related Videos

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer04:20

Author Spotlight: Exploring the Role of FAM83A in Cervical Cancer

Published on: February 9, 2024

1.3K
Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo09:19

Evaluating the Effectiveness of Cancer Drug Sensitization In Vitro and In Vivo

Published on: February 6, 2015

9.0K

Related Concept Videos

Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
5.0K
Induced Pluripotent Stem Cells01:06

Induced Pluripotent Stem Cells

Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
5.2K
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists01:27

Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists

5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
523
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
5.5K
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists01:28

Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists

Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy.  SP binds and activates...
458
Negative Regulator Molecules01:23

Negative Regulator Molecules

Positive regulators allow a cell to advance through cell cycle checkpoints. Negative regulators have an equally important role as they terminate a cell’s progression through the cell cycle—or pause it—until the cell meets specific criteria.
38.1K